Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa randomized open-label study of sodium danshensu injection for coronary microvascular disease
CTR20233687Phase 2Active
- Sponsor
- Naval Medical University
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of danshensu in Coronary Small Vessel Disease (CMD), angina pectoris and coronary arteriosclerosis (3 arms), sponsored by Naval Medical University. Primary endpoint: Change in SPECT parameters from baseline. Started May 2024; status: active.
02
Drugs
danshensu
03
Conditions
Coronary Small Vessel Disease (CMD)angina pectoriscoronary arteriosclerosis
Beyond the preview
Go deeper on CTR20233687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233687.